Patient Preferences for Breast Cancer Treatments: A Discrete Choice Experiment in France, Ireland, Poland and Spain
Eugena Stamuli, Sorcha Corry, Derek Ross, T. Konstantopoulou, Luis Texeira, Bernard Avouac, Dominique Debiais, L.R. Yates, Arni Behis, Ambrose McLoughlin, Federacja Stowarzyszeń Amazonki, Maciej Niewada, Ana Casas, Jaime Espín
Abstract
Aim: To understand breast cancer patients’ trade-offs when choosing treatments and to identify the most important treatment attributes which drive decisions. Materials & methods: A discrete choice experiment was conducted in France, Ireland, Poland and Spain. Progression-free survival, febrile neutropenia, pain, functional well-being and out-of-pocket payment were the treatment attributes. Results: 371 patients were willing to pay €6896 per year for 1 additional year of progression-free survival, €17,288 per year for perfect functional well-being and €15,138 for one pain-free year. Patients are willing to trade off progression-free survival months for better functional abilities and less pain. Conclusion: Patient preferences should be considered by regulatory agencies, reimbursement bodies, payors and clinicians for best treatment choices for the individuals.